Phase 4 Multiple Sclerosis Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with relapsing-remitting MS (RMS) or primary progressive MS (PPMS) based on a specific set of diagnostic standards called the 2017 McDonald criteria.
- People whose MS-related disability level, measured on a standard scale called the EDSS, falls between 0 and 6.5 at the time of screening or within the 6 months before screening.
- People who are stopping a type of MS medication called anti-CD20 (aCD20) therapy for reasons such as personal or doctor preference, difficulty accessing the medication (for example, insurance issues), or practical reasons like moving to a new area or travel difficulties.
- People who have previously been treated with one of the following anti-CD20 medications: ofatumumab (given by injection under the skin), ublituximab-xiiy (given by IV drip), or ocrelizumab (given by IV drip).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose MS did not respond well enough to anti-CD20 therapy.
- People who are stopping anti-CD20 therapy because of serious side effects, specifically: a severe allergic or infusion reaction rated grade 3 or higher, or repeated serious infections (grade 3 or higher) or needing two or more courses of antibiotics after starting anti-CD20 therapy, if the trial doctor believes the infections are related to the medication.
- People who cannot receive a type of MRI contrast dye called gadolinium, or who are unable to have an MRI scan for any reason.
- People with a known active, returning, or long-term infection such as HIV, syphilis, HPV, or tuberculosis.
- People with a history of a confirmed or suspected serious brain infection called progressive multifocal leukoencephalopathy (PML).
- People with other known neurological conditions that could make it difficult to clearly diagnose RMS or PPMS.
- People who have another condition that may require treatment with steroid medications or immune-suppressing drugs during the trial.
- People with a known allergy or sensitivity to ocrelizumab or any of the ingredients in the version of the medication being studied.
- People who have previously had a bone marrow transplant or a stem cell transplant.
- People who received a live vaccine within 6 weeks before the start of the trial.
- People who have undergone any experimental treatments for RMS or PPMS, such as procedures targeting a condition called chronic cerebrospinal venous insufficiency.
- People who have previously been treated with any of the following medications: cladribine, atacicept, alemtuzumab, or mitoxantrone.
- People who test positive for hepatitis B or hepatitis C antibodies at screening.
- Additional criteria not listed here may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S.)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With no Change or Reduction From Baseline in Number of T1 Gadolinium-enhanced (Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.